Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients
- 1 October 2016
- journal article
- research article
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (5) , 578-585
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma CellsEndocrinology, 2015
- Update in Adrenocortical CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2013
- Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cellsEndocrine-Related Cancer, 2013
- Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen ReplacementThe Journal of Clinical Endocrinology & Metabolism, 2013
- Approach to the Patient with Adrenocortical CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2010
- Adjuvant Therapy in Patients With Adrenocortical Carcinoma: A Position of an International PanelJournal of Clinical Oncology, 2010
- Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinomaCancer, 2009
- Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive PatientsThe Journal of Clinical Endocrinology & Metabolism, 2006
- Adrenocortical Carcinoma: Clinical UpdateThe Journal of Clinical Endocrinology & Metabolism, 2006
- Management of adrenocortical carcinomaClinical Endocrinology, 2003